Drug Approval | December 20, 2023
Briefs: Aurobindo Pharma and Granules Pharmaceuticals
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
10+ emerging markets, Japan & ANZ transition in final phase
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
Laurus Synthesis receives Form 483 with 5 observations from USFDA
The product will be manufactured at Lupin's Pithampur facility in India
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Atlas Life Sciences (India) has successfully commenced the commercial production of API - Intermediate at its new plant at Chhatral,
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Subscribe To Our Newsletter & Stay Updated
